Monthly Prescribing Reference

Gonal-f RFF Redi-ject Now Available

EMD Serono announced that Gonal-f RFF Redi-ject (recombinant follitropin alfa), a disposable prefilled drug injector pen intended for subcutaneous injection of a liquid formulation of Gonal-f RFF ...
Monthly Prescribing Reference

GONAL-f RFF Redi-ject Pen Approved

Merck Serono announced that the FDA has approved EMD Serono‘s GONAL-f RFF Redi-ject (recombinant follitropin alfa) injection, a disposable prefilled drug injector pen indicated for the subcutaneous ...
Business Insider

EMD Serono to Present Real-World Data Analyses at the Annual Pacific Coast Reproductive Society Meeting

ROCKLAND, Mass., March 22, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced two new real-world data analyses ...
Business Wire

EMD Serono Receives FDA Approval for Redesigned Fertility Pen

Gonal-f ® RFF Redi-ject™ (follitropin alfa injection) is indicated for: Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to ...
Medscape

FDA Drug and Device Approvals: June 3, 2004

The U.S. Food and Drug Administration has approved trospium chloride for the treatment of overactive bladder, a new device that delivers follitropin alpha for infertility, a new indication for ...